Hostname: page-component-7bb8b95d7b-cx56b Total loading time: 0 Render date: 2024-09-06T09:17:49.807Z Has data issue: false hasContentIssue false
  • English
  • Français

N Alpha Methyl Histamine Versus Propranolol in Migraine Prophylaxis

Published online by Cambridge University Press:  23 September 2014

R.O. Millán-Guerrero ,
R. Isais-Millán ,
B. Guzmán-Chávez  and
G. Castillo-Varela
R.O. Millán-Guerrero
Affiliation:
Unidad de Investigación en Epidemiología Clínica, Department of Neurology, Instituto Mexicano del Seguro Social, Colima, Col
R. Isais-Millán
Affiliation:
Departamento de Anestesiología, Hospital de Especialidades Médicas, Centro Médico Nacional, La Raza, IMSS, México
B. Guzmán-Chávez
Affiliation:
Departamento de Anestesiología, Hospital de Especialidades Médicas, Centro Médico Nacional, La Raza, IMSS, México
G. Castillo-Varela
Affiliation:
Unidad de Investigación en Epidemiología Clínica, Department of Neurology, Instituto Mexicano del Seguro Social, Colima, Col
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives:

To compare the efficacy and tolerability of the subcutaneous administration of N alpha methyl histamine versus oral propranolol in the treatment of migraine prophylaxis.

Background:

N alpha methyl histamine has a selective affinity for H3 receptors and could constitute a new therapeutic drug in migraine prophylaxis.

Methods:

Sixty patients with migraine were selected and enrolled in a 12-week double-blind controlled clinical trial to evaluate the efficacy of subcutaneous administration of N-alpha methyl histamine (1 to 3 ug twice a week ) n=30, compared to administration of 120 mg/day of oral propranolol n=30. the variables were: headache intensity, frequency of attacks, duration of migraine attacks and analgesic intake.

Results:

fifty five patients completed the study. the data collected during the 4th week of treatment revealed that N alpha methyl histamine and propranolol caused a significantly (p<0.01) greater reduction between the basal values and final values of every variable studied.

Conclusions:

Both N alpha methyl histamine and propranolol are similarly effective in reducing or eliminating the headache in migraine prophylaxis. low doses of N-alpha methyl histamine injected subcutaneously may represent a novel and effective therapeutic alternative in migraine patients and may lay the clinical and pharmacological groundwork for the use of H3 receptor agonist in migraine prophylaxis.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 41 , Issue 2 , March 2014 , pp. 233 - 238
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia. 1988;8 (Suppl. 7):1–96.Google Scholar
2.International classification of headache disorders-II. Cephalalgia. 2004;24(Supp 1):1–52.Google Scholar
3.Lipton, RB, Bigal, ME.Ten lessons on the epidemiology of migraine. Headache. 2007;47(Suppl. 1):S2–9.CrossRefGoogle ScholarPubMed
4.Linde, M, Gustavsson, A, Stovner, LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703–11.Google Scholar
5.Lipton, RB, Bigal, ME, Diamond, M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.Google Scholar
6.Holland, S, Silberstein, SD, Freitag, F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1346–53.CrossRefGoogle Scholar
7.Buchanan, TM, Ramadan, M.Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006;26:188–98.Google Scholar
8.Lohman, J, Van der Kuy-de Ree, M.Patterns of specific antimigraine drug use-a study based on the records of 18 community pharmacies. Cephalalgia. 2005;25:214–18.CrossRefGoogle ScholarPubMed
9.Shields, KG, Goadsby, PJ.Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain. 2005;128:86–97.Google Scholar
10.Sanchez-Del-Rio, M, Reuter, U, Moskowitz, MA.New insights into migraine pathophysiology. Curr Opin Neurol. 2006; 19:294–8.Google Scholar
11.Moskowitz, MA.The neurobiology of vascular head pain. Ann Neurol. 1984;16:157–68.CrossRefGoogle ScholarPubMed
12.Millán, GR, Isais, CM, Antonio, OA, et al. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache. 1999;39:576–80.Google Scholar
13.Ishikawa, S, Speralakis, N.A novel class H3 of histamine receptors on perivascular nerve terminals. Nature. 1987;327:158–60.CrossRefGoogle ScholarPubMed
14.Göthert, M, Garbarg, M, Hey, J A, et al. New aspects of the role of histamine in cardiovascular function: Identification, characterization, and potential pathophysiological importance of H3 receptors. Can J Pharmacol. 1995;73:558–64.Google Scholar
15.Millán, GR, Pineda, LA, Trujillo, HB, et al. N alpha methyl histamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies. Headache. 2003;43:389–94.Google Scholar
16.Millán-Guerrero, RO, Isais-Millán, R, Trujillo Hernández, B, et al. N alpha methyl histamine safety and efficacy in migraine prophylaxis: Phase III study. Can J Neurol Sci. 2006;33:195–9.CrossRefGoogle Scholar
17.Silberstein, SD, Holland, S, Freitag, F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.Google Scholar
18.International Classification of Headache Disorders, Olesen, J.International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions. Cephalalgia. 2006;26:1409–10.Google Scholar
19.Lipchik, GL.Nicholson, RA, Penzien, DB.Allocation of patients to conditions in headache clinical trials: randomization, stratification and treatment matching. Headache. 2005;45: 419–28.Google Scholar
20.International Headache Society committee on clinical trials in migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia. 1991;11:1–12.Google Scholar
21.Hulley, SB, Gove, S, Cummings, SR.Elección de los individuos que participarán en el estudio: especificación y muestreo. En: Hulley, SB, Cummings, SR, editors. Diseño de la Investigación Clínica. España: Harcourt Brace; 1997. p.21–55.Google Scholar
22.Lassen, LH.Thomsen, LL.Olesen, J.Histamine induce migraine via the H1 receptor. Support for the NO hypothesis of migraine. Neuroreport. 1995;6:1475–9.Google Scholar
23.Thomsen, LL, Olesen, JB.Nitric oxide in primary headache. Curr Opin Neurol. 2001;14:315–21.CrossRefGoogle Scholar
24.Peroutka, SJ.Neurogenic inflammation and migraine: Implications for therapeutics. Mol Interv. 2005;5:304–11.Google Scholar
25.Arrang, JM, Garbarg, M, Schwartz, JC.Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature. 1983;302:832–7.CrossRefGoogle ScholarPubMed
26.Arrang, J-M, Garbarg, M, Schwartz, J-C.Autoinhibition of histamine synthesis mediated by presynaptic H3-receptors. Neuroscience. 1987;23:149–57.Google Scholar
27.Waeber, CH, Moskowitz, MA.Migraine as an inflammatory disorder. Neurology. 2005;64(Suppl 2); S9–15.CrossRefGoogle ScholarPubMed
28.West, RE, Zweig, A, Shih, N-Y, et al. Identification of two H3-histamine receptor subtypes. Mol Pharmacol. 1990;38:610–13.Google ScholarPubMed
29.Dimitriadou, V, Rouleau, A, Trung, Dam, et al. Functional relationship between mast cells and C-sensitive nerve fibers evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci. 1994;87:151–63.Google Scholar
30.Tokita, S, Takahashi, K, Kotani, H.Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine h3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders. J Pharmacol Sci. 2006;101:12–18.CrossRefGoogle ScholarPubMed
31.Olesen, J, Diener, HC, Husstedt, IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New Engl J Med. 2004;350:1104–10.CrossRefGoogle ScholarPubMed
32.Goadsby, PJ.Recent advances in the diagnosis and management of migraine. Brit Med J. 2006;332:25–9.Google Scholar
33.Loder, E.Prophylaxis: headaches that never happen. Headache. 2008;48:694–6.Google Scholar
34.Marmura, MJ, Silbertein, S.Current understanding and treatment of headache disorders. Neurol Clin Pract. 2011;76 (Suppl 2):S31–6.Google Scholar
35.Durham, PL, Masterson, CG.Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache. 2013;53:67–80.CrossRefGoogle ScholarPubMed
36.Sieberg, CHB, Huguet, A, Von Baeyer, CL, et al. Psychological interventions for headache in children and adolescents. Can J Neurol Sci. 2012;39:26–34.Google Scholar